Dramatically, ILC3s expresses the major histocompatibility complex class II (MHC II) to drive type-1 immunity that inhibits microbiota-specific effector CD4+ T cell responses, which is sensitive to anti-PD-1 immunotherapy in colon cancer [37]. This evidence concerns the gene CD4 and malignant colon neoplasm.